维得利珠单抗治疗炎症性肠病的应答。两年随访。
Vedolizumab response in inflammatory bowel disease. Two years of follow-up.
机构信息
Aparato Digestivo, Hospital Universitario Virgen Macarena, España.
Aparato Digestivo, Hospital Universitario Virgen Macarena.
出版信息
Rev Esp Enferm Dig. 2020 Jul;112(7):555-558. doi: 10.17235/reed.2020.7130/2020.
BACKGROUND
vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab.
METHODS
this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three, six, 12, 18 and 24 months after induction.
RESULTS
fifty-five patients were included. Clinical remission rates in CD and UC at three, six, 12, 18 and 24 months were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %, 26.09 %, 19.05 %, 26.67 % and 20 %, respectively.
CONCLUSIONS
vedolizumab is effective for induction and maintenance of clinical remission, both in Crohn's disease and ulcerative colitis.
背景
vedolizumab 是一种 α4β7 整合素拮抗剂。本研究旨在评估 vedolizumab 的临床应答率和缓解率。
方法
这是一项回顾性研究，纳入了 2016 年至 2019 年间接受 vedolizumab 治疗的炎症性肠病（IBD）患者。在诱导治疗后 3、6、12、18 和 24 个月时分析应答和缓解率。
结果
共纳入 55 例患者。CD 和 UC 在诱导治疗后 3、6、12、18 和 24 个月的临床缓解率分别为 19.35%、26.67%、30.43%、30%、38.89%和 29.17%、26.09%、19.05%、26.67%和 20%。
结论
vedolizumab 对克罗恩病和溃疡性结肠炎的诱导和维持临床缓解均有效。
Zotero 插件